Preferred Label : Vanucizumab;
NCIt synonyms : Ang2-VEGF-A CrossMab RO5520985; Immunoglobulin Recombined G1-kappa/lambda, Anti-(Homo sapiens Angpt2 (Angiopoietin
2, Ang2))/Anti-Homo sapiens VEGFa (Vascular Endothelial Growth Factor A, VEGF-a, VEGF)),
Humanized Monoclonal Antibody;
NCIt definition : A humanized bispecific immunoglobulin G (IgG1) monoclonal antibody targeting both
the vascular endothelial growth factor receptor (VEGFR) ligand VEGF-A and the Tie2
receptor ligand angiopoietin-2 (Ang-2), with potential antineoplastic and anti-angiogenic
activities. Upon administration of vanucizumab, the anti-VEGF-A arm, which is based
on bevacizumab, targets and binds to VEGF-A and the anti-Ang2 arm, which is based
on the anti-Ang-2 antibody LC06, targets and binds to Ang2, thereby simultaneously
binding and neutralizing both VEGF-A and Ang2. This prevents the activation of both
VEGF-A/VEGFR- and Ang2/Tie2-mediated signaling pathways. Altogether, this results
in the inhibition of proliferation of VEGF-A- and/or Ang2-overexpressing tumor cells.
VEGF-A and Ang2, both upregulated in a variety of tumor cell types, play key roles
in tumor cell proliferation, angiogenesis and metastasis.;
UNII : B800Z06O8K;
CAS number : 1448221-05-3; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1448221-05-3
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Molecule name : RO-5520985; RG-7221;
NCI Metathesaurus CUI : CL446653;
Origin ID : C118578;
UMLS CUI : C4331496;
Automatic exact mappings (from CISMeF team)
- Currated CISMeF NLP mapping
- Semantic type(s)
- UMLS correspondences (same concept)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
